NVP-LCQ195 is primarily investigated for its potential therapeutic applications in the field of oncology. It is a selective inhibitor targeting specific protein kinases involved in cancer cell proliferation and survival. By inhibiting these kinases, NVP-LCQ195 disrupts signaling pathways that are crucial for tumor growth, making it a promising candidate for cancer treatment. Preclinical studies have shown its efficacy in reducing tumor size and inhibiting metastasis in various cancer models. Researchers are also exploring its potential in combination therapies to enhance the effectiveness of existing cancer treatments. Additionally, its selectivity may help minimize off-target effects, improving patient outcomes and reducing side effects associated with conventional chemotherapy. Ongoing research aims to further validate its safety and efficacy in clinical trials.